Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant
IBER.U
IBER.U was delisted on the 1st of March, 2023.
34 hedge funds and large institutions have $61.7M invested in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 26 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
43% less funds holding
Funds holding: 60 → 34 (-26)
49% less capital invested
Capital invested by funds: $121M → $61.7M (-$59.6M)
96% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$306K |
| 2 |
Janus Henderson Group
London,
|
+$266K |
| 3 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
+$109K |
| 4 |
Jane Street
New York
|
+$65.5K |
| 5 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$10K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$5.47M |
| 2 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$4.93M |
| 3 |
KC
Kepos Capital
New York
|
-$4.88M |
| 4 |
LA
Linden Advisors
New York
|
-$4.44M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$4.44M |
IBER.U Hedge Fund Activity: Q2 2021 in Review
34 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) for Q2 2021, worth a combined $61.7M — down 49% from $121M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of IBER.U and 1 opened new positions — a net loss of 25 holders — while 8 trimmed existing stakes and 6 added.
The largest buyer was D.E. Shaw & Co, adding an estimated $306K. The largest seller was Citadel Advisors, cutting an estimated $5.47M.
- 34 institutional investors held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) as of Q2 2021, down from 60 in Q1 2021.
- Funds reported $61.7M of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant stock for Q2 2021, down 49% quarter-over-quarter.
- 1 fund opened new Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant positions in Q2 2021 and 26 closed out, a net change of -25 holders.
- The largest Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant buyer in Q2 2021 was D.E. Shaw & Co, an estimated $306K added.
- The largest Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant seller in Q2 2021 was Citadel Advisors, an estimated $5.47M sold.
Based on aggregated 13F filings for Q2 2021.